What are the National Comprehensive Cancer Network (NCCN) preferred regimens for systemic therapy in renal cell carcinoma (RCC)?

Updated: Jun 08, 2020
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

The 2019 National Comprehensive Cancer Network (NCCN) kidney cancer guideline recommends that for relapsed or stage IV clear cell kidney cancer, preferred regimens are as follows:

  • Favorable risk patients –  Pazopanib or sunitinib 
  • Poor or intermediate risk patients –  Ipilimumab + nivolumab  or cabozantinib

For subsequent therapy, preferred regimens are cabozantinib or nivolumab.

For relapsed or stage IV non–clear cell kidney cancer, the NCCN recommends participation in a clinical trial. Sunitinib is the only preferred regimen.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!